High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone.
The prognosis of patients with peripheral T-cell lymphoma (PTCL) treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) is poor, but their laboratory prognostic parameters had not previously been evaluated. We retrospectively reviewed 55 patients with newly diagnosed PTCL treated with CHOP from August 1999 to May 2009 at our institution. We analyzed six laboratory parameters, including thymidine kinase (TK) activity, to evaluate overall survival, which was the primary end-point. In multivariate analysis, the overall survival was significantly worse in patients with high TK activity (hazard ratio 34.8, 95% confidence interval [CI] 1.03-1176.23). The overall response rate among patients with high TK activity was 21.4%, significantly poorer compared with other parameters (p = 0.001). High TK activity predicts poor overall survival among patients with newly diagnosed PTCL treated with CHOP. Response to CHOP treatment is significantly decreased in patients with PTCL with high TK activity.
Department of Medical Hematology/Oncology, Cancer Institute Hospital, Tokyo, Japan.
Kazuhito
K
Suzuki
Yasuhito
Y
Terui
Kenji
K
Nakano
Eriko
E
Nara
Kentaro
K
Nasu
Kyoko
K
Ueda
Noriko
N
Nishimura
Yuko
Y
Mishima
Sakura
S
Sakajiri
Masahiro
M
Yokoyama
Shunji
S
Takahashi
Kiyohiko
K
Hatake
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004317:Doxorubicin; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D011237:Predictive Value of Tests; D011241:Prednisone; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013937:Thymidine Kinase / Q000378:metabolism*; D014750:Vincristine
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D013937:Thymidine Kinase; D011241:Prednisone